Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KMT2A | Q03164 | 1/20 | 0.52 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.43 |
| ▸ | GRM5 | P41594 | 1/20 | 0.37 |
| ▸ | P2RX3 | P56373 | 2/20 | 0.36 |
| ▸ | BUB1 | O43683 | 1/20 | 0.34 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.34 |
| ▸ | HPGD | P15428 | 1/20 | 0.34 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.33 |
| ▸ | HSD11B1 | P28845 | 1/20 | 0.33 |
| ▸ | MAPT | P10636 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL7096693 | 1.00 | KMT2A (0.52) | KMT2AMAPK1GRM5P2RX3BUB1 | |
| SCHEMBL34474138 | 0.85 | KMT2A (0.47) | KMT2AMAPK1ALDH1A1CYP2D6 | |
| SCHEMBL4714422 | 0.84 | KMT2A (0.51) | KMT2AMAPK1GRM5P2RX3ALDH1A1 | |
| SCHEMBL10306172 | 0.82 | KMT2A (0.54) | KMT2AMAPK1GRM5P2RX3ALDH1A1 | |
| SCHEMBL9682608 | 0.80 | CYP2D6 (0.45) | ALDH1A1CYP2D6 | |
| SCHEMBL28778762 | 0.80 | KMT2A (0.52) | KMT2AMAPK1GRM5P2RX3BUB1 | |
| SCHEMBL28778765 | 0.80 | KMT2A (0.52) | KMT2AMAPK1GRM5P2RX3BUB1 | |
| SCHEMBL28778767 | 0.80 | KMT2A (0.52) | KMT2AMAPK1GRM5P2RX3BUB1 | |
| SCHEMBL15850846 | 0.80 | KMT2A (0.52) | KMT2AMAPK1GRM5P2RX3ALDH1A1 | |
| SCHEMBL13495538 | 0.80 | KMT2A (0.61) | KMT2AMAPK1GRM5P2RX3ALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20030114666-A1 | Having quinazolindione core structure; non-antibiotic resistance | WARNER-LAMBERT COMPANY | 2003-06-19 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030114666-A1 | Having quinazolindione core structure; non-antibiotic resistance | ABCC1, RPS6KA1, SIGMAR1 | KMT2A 3440/4885MAPK1 544/4885GRM5 2861/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.